Lonza Signs Agreement to Divest Specialty Ingredients Business to Bain Capital and Cinven
- Lonza Specialty Ingredients to be sold to Bain Capital and Cinven for an enterprise value of CHF 4.2 billion
- Divestment will allow Lonza to refocus its business as a pure-play partner to the healthcare industry
- Successful track record of investment in industrials sector and portfolio companies confirms that Bain Capital and Cinven are the right home for the business
- Smooth transition for employees and customers is a priority for both seller and buyers. The transaction is anticipated to close in H2 2021